2012 || Oncology || Hormone Refractory Breast Cancer – Pipeline Review, H2 2012 || Aarkstore.com

1. Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Hormone Refractory Breast Cancer – Pipeline Review, H2
2012
http://www.aarkstore.com/reports/Hormone-Refractory-Breast-Cancer-
Pipeline-Review-H2-2012-220601.html
RSS link of Global Markets Direct
http://www.aarkstore.com/feeds/Global-Markets-Direct.xml
Summary
Global Markets Direct’s, Hormone Refractory Breast Cancer - Pipeline Review, H2
2012, provides an overview of the Hormone Refractory Breast Cancer therapeutic
pipeline. This report provides information on the therapeutic development for
Hormone Refractory Breast Cancer, complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Hormone Refractory Breast Cancer.
Hormone Refractory Breast Cancer - Pipeline Review, H2 2012 is built using data
and information sourced from Global Markets Direct’s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hormone Refractory Breast

2. Cancer.
- A review of the Hormone Refractory Breast Cancer products under development
by companies and universities/research institutes based on information derived
from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
- Coverage of the Hormone Refractory Breast Cancer pipeline on the basis of route of
administration and molecule type.
- Profiles of late-stage pipeline products
Table of contents:
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hormone Refractory Breast Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hormone Refractory Breast Cancer 7
Hormone Refractory Breast Cancer Therapeutics under Development by Companies
9
Hormone Refractory Breast Cancer Therapeutics under Investigation by
Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Hormone Refractory Breast Cancer Therapeutics – Products under Development by
Companies 14
Hormone Refractory Breast Cancer Therapeutics – Products under Investigation by
Universities/Institutes 15
Companies Involved in Hormone Refractory Breast Cancer Therapeutics

3. Development 16
Bristol-Myers Squibb Company 16
Aragon Pharmaceuticals, Inc. 17
Hormone Refractory Breast Cancer – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Fulvestrant + Lapatinib - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Doxorubicin + Cyclophosphamide -
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1
Cholangiocellular Hepatoma – Pipeline Review, H2 2012
Hormone Refractory Breast Cancer – Pipeline Review, H2 2012
Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012

4. Refractory Multiple Myeloma – Pipeline Review, H2 2012
Epithelial Ovarian Cancer – Pipeline Review, H2 2012
Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012
B-Cell Leukemia – Pipeline Review, H2 2012
Malignant Neoplasms – Pipeline Review, H2 2012
Recurrent Malignant Glioma – Pipeline Review, H2 2012
Endobronchial Cancer – Pipeline Review, H2 2012
Leiomyosarcoma – Pipeline Review, H2 2012
Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012
Esophageal Tumor – Pipeline Review, H2 2012
Malignant Pleural Mesothelioma – Pipeline Review, H2 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1
You can also request for sample page of above mention reports on
sample@aarkstore.com

5. For More details Plz do contact :
Aarkstore Enterprise
Lavanya
Phone:08149852585
Email: enquiry@aarkstore.com